MEDICAL SERVICES

Specialties

Departments

Programs

Languages

  • English

EDUCATION

Medical School

  • New York University School of Medicine , 2001 , New York , NY

Residency

  • University of Chicago , 2004 , Chicago , IL

Fellowship

  • University of Chicago , 2008 , Chicago , IL

PROFESSIONAL HISTORY

Dr. Stacy Kahn completed her undergraduate degree in history at Washington University in St. Louis, and her post-baccalaureate premedical training at Bryn Mawr College in Pennsylvania. She attended New York University School of Medicine and then went on to complete her pediatric residency and pediatric gastroenterology fellowship at the University of Chicago. While at the University of Chicago, she also completed an ethics fellowship at the Maclean Center for Clinical Medical Ethics.

Clinically, Dr. Kahn’s interests have focused on the care of children with IBD, in particular she is interested in the care and management of teens and young adults with Crohn’s and colitis. While on the faculty at the University of Chicago, she founded and was the Director for the Transitional IBD Clinic. Dr. Kahn's other primary clinical focus is recurrent and refractory Clostridium difficile infection. She is a national expert and leader in the field of fecal microbiota transplantation (FMT) and performed the first colonoscopic FMT in a child.

Dr. Kahn's research interests include FMT for Clostridium difficile, FMT for inflammatory bowel disease, transition of care and self-management in IBD and research ethics. She is the director of the FMT research program at Boston Children’s Hospital and has led the development of the first national pediatric FMT registry.

CERTIFICATIONS

  • American Board of Pediatrics, Pediatric Gastroenterology

PUBLICATIONS

Publications powered byHarvard Catalyst Profiles

  1. Updates and Challenges in Fecal Microbiota Transplantation for Clostridioides difficile Infection in Children. J Pediatr Gastroenterol Nutr. 2021 10 01; 73(4):430-432.View abstract
  2. Fecal Microbiota Transplantation for Ulcerative Colitis: Dispelling the "Yuck Factor". J Pediatr Gastroenterol Nutr. 2021 Sep 28.View abstract
  3. Current Challenges in Fecal Microbiota Transplantation for Clostridioides difficile Infection in Children. Am J Gastroenterol. 2021 09 01; 116(9):1954-1956.View abstract
  4. Fecal Calprotectin Is Highly Effective to Detect Endoscopic Ulcerations in Crohn's Disease Regardless of Disease Location. Inflamm Bowel Dis. 2021 06 15; 27(7):1008-1016.View abstract
  5. Fecal Microbiota Transplantation for Recurrent C difficile Infection During the COVID-19 Pandemic: Experience and Recommendations. Mayo Clin Proc. 2021 06; 96(6):1418-1425.View abstract
  6. 炎症性肠病与Concurr呈现ent COVID-19 Multisystem Inflammatory Syndrome. Pediatrics. 2021 04; 147(4).View abstract
  7. The Ethics of Feeding the Aspirating Child in an Age of Increasing Patient Complexity. J Pediatr Gastroenterol Nutr. 2020 11; 71(5):586-588.View abstract
  8. Fecal Microbiota Transplantation Is Highly Effective in Real-World Practice: Initial Results From the FMT National Registry. Gastroenterology. 2021 01; 160(1):183-192.e3.View abstract
  9. The Ethics of Feeding the Aspirating Child in an Age of Increasing Patient Complexity. J Pediatr Gastroenterol Nutr. 2020 Aug 20.View abstract
  10. Letter: is unrealised adult height resulting from paediatric Crohn's disease associated with a potential reduction in lifetime earnings? Aliment Pharmacol Ther. 2020 08; 52(3):559-560.View abstract
  11. Perceived effect of pediatric inflammatory bowel diseases on academics, college planning, and college adjustment. J Am Coll Health. 2020 Jul 09; 1-8.View abstract
  12. Is it unethical to conduct placebo-controlled trials of faecal microbiota transplantation for recurrent Clostridioides difficile infection? Lancet Gastroenterol Hepatol. 2020 05; 5(5):432-433.View abstract
  13. International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. Gut. 2019 12; 68(12):2111-2121.View abstract
  14. Faecal Calprotectin Is a Very Reliable Tool to Predict and Monitor the Risk of Relapse After Therapeutic De-escalation in Patients With Inflammatory Bowel Diseases. J Crohns Colitis. 2019 Aug 14; 13(8):1012-1024.View abstract
  15. Response to: Treatment of (Recurrent) Clostridioides difficile Infections in Children and Adults. J Pediatr Gastroenterol Nutr. 2019 08; 69(2):e58-e59.View abstract
  16. Risk-factors Associated With Poor Outcomes in VEO-IBD Secondary to XIAP Deficiency: A Case Report and Literature Review. J Pediatr Gastroenterol Nutr. 2019 07; 69(1):e13-e18.View abstract
  17. Efficacy of Fecal Microbiota Transplantation for Clostridium difficile Infection in Children. Clin Gastroenterol Hepatol. 2020 03; 18(3):612-619.e1.View abstract
  18. The Gut Microbiome: A Difficult Target for Translational Studies of Clostridium difficile Colonization. J Pediatr Gastroenterol Nutr. 2019 04; 68(4):463-464.View abstract
  19. Risk-factors Associated with Poor Outcomes in VEO-IBD Secondary to XIAP Deficiency: A Case Report and Literature Review. J Pediatr Gastroenterol Nutr. 2019 Feb 07.View abstract
  20. Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection and Other Conditions in Children: A Joint Position Paper From the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr. 2019 01; 68(1):130-143.View abstract
  21. Searching for superstool: maximizing the therapeutic potential of FMT. Nat Rev Gastroenterol Hepatol. 2018 07; 15(7):387-388.View abstract
  22. 粪便证明钙卫蛋白在评估内镜。并且tological Remission in Patients with Ulcerative Colitis. Dig Dis Sci. 2018 May; 63(5):1294-1301.View abstract
  23. Moving On: Transition Readiness in Adolescents and Young Adults With IBD. Inflamm Bowel Dis. 2018 02 15; 24(3):482-489.View abstract
  24. Indirect Costs and Family Burden of Pediatric Crohn's Disease in the United States. Inflamm Bowel Dis. 2017 12; 23(12):2089-2096.View abstract
  25. Reliability and validity of the Beliefs About Medication Scale in pediatric inflammatory bowel disease. J Child Health Care. 2017 Sep; 21(3):253-262.View abstract
  26. Tracking microbial colonization in fecal microbiota transplantation experiments via genome-resolved metagenomics. Microbiome. 2017 05 04; 5(1):50.View abstract
  27. What Teens Do Not Know Can Hurt Them: An Assessment of Disease Knowledge in Adolescents and Young Adults with IBD. Inflamm Bowel Dis. 2017 01; 23(1):89-96.View abstract
  28. Transition of Care for Adolescents and Young Adults With Inflammatory Bowel Disease: The More We Learn, The Less We Know. J Pediatr Gastroenterol Nutr. 2016 11; 63(5):451-452.View abstract
  29. Transition of Care for Adolescents and Young Adults with IBD: The More We Learn, the Less We Know. J Pediatr Gastroenterol Nutr. 2016 Jun 02.View abstract
  30. The Transition From Pediatric to Adult Inflammatory Bowel Disease Care. Gastroenterol Hepatol (N Y). 2016 Jun; 12(6):403-6.View abstract
  31. When Subjects Violate the Research Covenant: Lessons Learned from a Failed Clinical Trial of Fecal Microbiota Transplantation. Am J Gastroenterol. 2016 11; 111(11):1508-1510.View abstract
  32. Feeling Fine: Anxiety and Depressive Symptoms in Youth with Established IBD. Inflamm Bowel Dis. 2016 Feb; 22(2):402-8.View abstract
  33. Colonic Necrosis in a 4-Year-Old with Hyperlipidemic Acute Pancreatitis. Case Rep Pediatr. 2016; 2016:9123163.View abstract
  34. Genetic and Metabolic Signals during Acute Enteric Bacterial Infection Alter the Microbiota and Drive Progression to Chronic Inflammatory Disease. . 2016 Jan 13; 19(1):21-31.View abstract
  35. Whole-exome Sequence Analysis Implicates Rare Il17REL Variants in Familial and Sporadic Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016 Jan; 22(1):20-7.View abstract
  36. Can You Teach a Teen New Tricks? Problem Solving Skills Training Improves Oral Medication Adherence in Pediatric Patients with Inflammatory Bowel Disease Participating in a Randomized Trial. Inflamm Bowel Dis. 2015 Nov; 21(11):2649-57.View abstract
  37. 更新在粪便微生物群Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook. Gastroenterology. 2015 Jul; 149(1):223-37.View abstract
  38. Can we improve on the "see one, do one, teach one" paradigm in training fellows to care for patients with inflammatory bowel disease? Inflamm Bowel Dis. 2015 Apr; 21(4):766-7.View abstract
  39. Transition of Care in Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2014 Oct; 10(10):633-40.View abstract
  40. Trajectories of oral medication adherence in youth with inflammatory bowel disease. Health Psychol. 2015 May; 34(5):514-21.View abstract
  41. Fecal microbiota transplantation: an interest in IBD? Nestle Nutr Inst Workshop Ser. 2014; 79:101-14.View abstract
  42. Patient perceptions of fecal microbiota transplantation for ulcerative colitis. Inflamm Bowel Dis. 2013 Jun; 19(7):1506-13.View abstract
  43. Colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection in a child. Am J Gastroenterol. 2012 Dec; 107(12):1930-1.View abstract
  44. An unusual case of an infant with failure to thrive. Pediatr Ann. 2012 Dec; 41(12):502-5.View abstract
  45. What's in a name generator? Choosing the right name generators for social network surveys in healthcare quality and safety research. BMJ Qual Saf. 2012 Dec; 21(12):992-1000.View abstract
  46. Studying the Enteric Microbiome in Inflammatory Bowel Diseases: Getting through the Growing Pains and Moving Forward. Front Microbiol. 2011; 2:144.View abstract
  47. Fecal bacteriotherapy for ulcerative colitis: patients are ready, are we? Inflamm Bowel Dis. 2012 Apr; 18(4):676-84.View abstract
  48. Massive intestinal bleeding in a child with superior mesenteric artery aneurysm and gastrointestinal tuberculosis. J Pediatr Gastroenterol Nutr. 2006 Aug; 43(2):256-9.View abstract